USPTO serial 79417399
BCN PEPTIDES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LATTUCA, FRANK J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with BCN PEPTIDES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth Lee D'Amore
Elizabeth Lee D'Amore Lucas & Mercanti, LLP100 South Jefferson RoadSuite 202Whippany, NJ 07981Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for use in industry specifically for biotechnological product development; chemical products for use in pharmaceutical product manufacture; chemical products for manufacturing cosmetics; biological preparations for industry and science | ACTIVE | — |
| 005 | Pharmaceutical products, namely, pharmaceutical preparations for the treatment of cardiovascular diseases, of the central nervous system, namely, encephalitis, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, of respiratory diseases, namely, respiratory infections, asthma, bronchitis, pneumonia, of eating disorders, of musculo-skeletal disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, of urological, urogenital and urinary disorders, of dermatological diseases, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, rosacea, blotches; pharmaceutical products for medical use to treat metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases, gynecological conditions and conditions of the reproductive system; pharmaceutical products for veterinary use, namely, veterinary pharmaceutical preparations for the treatment of metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases and conditions of the reproductive system; pharmaceutical products for skin care; hygienic and sanitary products for medical use namely, disinfectants and sanitary sterilizing preparations; dietetic substances for medical use; dietetic substances namely, dietetic preparations adapted for veterinary use, food supplements for humans and animals; biological preparations for medical and veterinary use specifically cytostatic agents, hormones, diagnostic agents for medical purposes, anti-infective agents, blood clotting agents, blood anticoagulant agents, , veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia, respiratory infections, eye infections, topical infections | ACTIVE | — |
| 042 | Scientific and technological services as well as research and design related thereto, namely, scientific research, development, and design services relating to pharmaceuticals; industrial analysis and research services in the field of chemistry for medical purposese; pharmaceutical research services; research and development services in chemistry; research services relating to cosmetics; pharmaceutical research and product development services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 8, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 2, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 12, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 6, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 3, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 20, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 19, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 3, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 3, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 3, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 1, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 1, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 24, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 24, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 20, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |